rozanolixizumab: Clinical Trials

7 trials of rozanolixizumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 terminated. 7 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Completed 6, Terminated 1
Phase 31Completed 1

Follow rozanolixizumab: new trials by email Literature Review of rozanolixizumab trials Research Report on rozanolixizumab

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
rozanolixizumab - Generalized Myasthenia Gravis
Phase 2 / Phase 3CompletedUCB Biopharma SRL142024-06-142026-10-27
A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome
rozanolixizumab, Placebo - Fibromyalgia
Phase 2CompletedUCB Biopharma SRL632022-12-212025-07-01
A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Rozanolixizumab, Placebo - Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Phase 2TerminatedUCB Biopharma SRL122021-09-272025-05-31
A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Rozanolixizumab - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Phase 2CompletedUCB Biopharma SRL212019-08-212022-11-03
A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Rozanolixizumab, Placebo - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Phase 2CompletedUCB Biopharma S.P.R.L.342019-03-262023-08-01
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
UCB7665, Placebo - Myasthenia Gravis
Phase 2CompletedUCB Biopharma S.P.R.L.432017-05-152021-08-03
Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia
UCB7665 - Thrombocytopenia
Phase 2CompletedUCB Biopharma SRL662016-03-022024-01-29

Conditions studied

Myasthenia Gravis (2)  ·  Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (2)  ·  Fibromyalgia (1)  ·  Thrombocytopenia (1)

Sponsors

UCB Biopharma SRL (5)  ·  UCB Biopharma S.P.R.L. (2)

Countries

Germany (5)  ·  Spain (5)  ·  United Kingdom (5)  ·  Belgium (4)  ·  United States (4)  ·  Denmark (3)  ·  France (3)  ·  Italy (3)  ·  Netherlands (3)  ·  Australia (2)  ·  Czechia (2)  ·  Poland (2)  ·  Bulgaria (1)  ·  Canada (1)  ·  Georgia (1)

Results publications

PMID 30130439, PMID 38729747, PMID 32886753, PMID 33219142, PMID 37166675, PMID 38099334, PMID 42748952

NIH funding

2016 (2), 2018 (1), 2019 (1)